Produktbild: The Maudsley Deprescribing Guidelines

The Maudsley Deprescribing Guidelines Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs

59,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

15.02.2024

Verlag

John Wiley & Sons Inc

Seitenzahl

592

Maße (L/B/H)

24,5/17,3/3,5 cm

Gewicht

1089 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-1-119-82298-1

Beschreibung

Rezension

"This book provides a unique and detailed guide to deprescribing psychiatric medication. It is a welcome companion volume to the Maudsley Prescribing Guidelines in Psychiatry which have been essential and highly valued reading for psychiatrists for the past 30 years."
--Professor Wendy Burn, Past President Royal College of Psychiatrists
 
"Psychiatrists are bombarded with information on how to start and continue medications for their patients. However, they receive little or no information on how and when to decrease or stop medications. These guidelines fill that gap."
--Sir Professor Robin Murray, Professor of Psychiatric Research
 
"Since we began using psychiatric medications 60 years ago, the focus has been on prescribing- with almost no attention to withdrawal symptoms & how often they're confused with relapse. Any clinician can prescribe drugs; it takes art, science, and people skills to deprescribe them."
--Professor Allen Frances, Professor Emeritus of psychiatry at Duke University and head of the DSM-IV committee

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

15.02.2024

Verlag

John Wiley & Sons Inc

Seitenzahl

592

Maße (L/B/H)

24,5/17,3/3,5 cm

Gewicht

1089 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-1-119-82298-1

EU-Ansprechpartner

Zeitfracht Medien GmbH
Ferdinand-Jühlke-Straße 7
99095 Erfurt
DE
produktsicherheit@zeitfracht.de

Herstelleradresse

Wiley & Sons
1 Oldlands Way
PO22 9NQ Bognor Regis
GB
trade@wiley.com

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern

Die Leseprobe wird geladen.
  • Produktbild: The Maudsley Deprescribing Guidelines
  • Preface ix

    Acknowledgements xii

    Notes on Using the Maudsley® Deprescribing Guidelines xiii

    Abbreviations List xv

    Chapter 1 Introduction to Deprescribing Psychiatric Medications 1

    Deprescribing as an Intervention 1

    The context for deprescribing 2

    Why deprescribe? 7

    Barriers and facilitators to deprescribing 11

    Withdrawal Effects from Psychiatric Medications 13

    Mis-diagnosis of withdrawal effects as relapse 13

    Pathophysiology of psychiatric drug withdrawal symptoms 16

    Clinical aspects of psychiatric drug withdrawal 19

    Specific issues in psychiatric drug withdrawal 23

    How to Deprescribe Psychiatric Medications Safely 27

    The neurobiology of tapering 28

    Practical options for prescribing gradually tapering doses 36

    Psychological aspects of tapering 43

    Tapering psychiatric drugs in practice 45

    Further topics 52

    Chapter 2 Safe Deprescribing of Antidepressants 57

    When and Why to Stop Antidepressants 57

    Adverse effects of antidepressants 66

    Discussing deprescribing antidepressants with patients 72

    Withdrawal Effects from Antidepressants 76

    Recent developments in the understanding of antidepressant withdrawal 76

    Pathophysiology of antidepressant withdrawal symptoms 80

    Clinical aspects of antidepressant withdrawal 87

    How common, severe and long¿ lasting are withdrawal symptoms from antidepressants? 92

    Protracted antidepressant withdrawal syndrome 96

    Post¿ SSRI sexual dysfunction 98

    Factors influencing development of withdrawal effects 99

    Stratfiying risk of antidepressant withdrawal 105

    Distinguishing antidepressant withdrawal symptoms from relapse 107

    Distinguishing antidepressant withdrawal symptoms from new onset of a physical or mental health condition 111

    Withdrawal symptoms during antidepressant maintenance treatment or switching medication 113

    How to Deprescribe Antidepressants Safely 115

    Tapering antidepressants gradually 119

    Hyperbolic tapering of antidepressants 125

    Practical options in prescribing gradually tapering doses of antidepressants 131

    Psychological aspects of antidepressant tapering 140

    Tapering antidepressants in practice 143

    Managing complications of antidepressant discontinuation 153

    Tapering Guidance for Specific Antidepressants 158

    Agomelatine 159

    Amitriptyline 163

    Bupropion 168

    Citalopram 174

    Clomipramine 183

    Desvenlafaxine 188

    Dosulepin 193

    Doxepin 198

    Duloxetine 203

    Escitalopram 209

    Fluoxetine 216

    Fluvoxamine 223

    Imipramine 228

    Lofepramine 233

    Mirtazapine 238

    Moclobemide 243

    Nortriptyline 248

    Paroxetine 253

    Phenelzine 259

    Sertraline 264

    Tranylcypromine 270

    Trazodone 275

    Venlafaxine 280

    Vilazodone 288

    Vortioxetine 292

    Chapter 3 Safe Deprescribing of Benzodiazepines and Z-drugs 297

    When and Why to Stop Benzodiazepines and Z-drugs 297

    Discussing deprescribing benzodiazepines and z-drugs 304

    Withdrawal Symptoms from Benzodiazepines and Z-drugs 309

    Physical dependence vs addiction in use of benzodiazepines and z-drugs 311

    Pathophysiology of benzodiazepine withdrawal syndrome 313

    Variety of withdrawal symptoms from benzodiazepines and z-drugs 316

    Protracted benzodiazepine withdrawal syndrome 320

    Distinguishing benzodiazepine withdrawal symptoms from return of an underlying condition 323

    Withdrawal symptoms during benzodiazepine maintenance treatment 326

    How to Deprescribe Benzodiazepines and Z-drugs Safely 327

    Tapering benzodiazepines and z-drugs gradually 330

    Hyperbolic tapering of benzodiazepines and z-drugs 332

    Switching to longer-acting benzodiazepines to taper 335

    Making up smaller doses of benzodiazepines and z-drugs practically 338

    Other considerations in tapering benzodiazepines and z-drugs 342

    Psychological aspects of tapering benzodiazepines and z-drugs 345

    Tapering benzodiazepines and z-drugs in practice 348

    Management of complications of benzodiazepine and z-drug discontinuation 358

    Tapering Guidance for Specific Benzodiazepines and Z-drugs 362

    Alprazolam 364

    Buspirone 375

    Chlordiazepoxide 380

    Clonazepam 388

    Clorazepate 396

    Diazepam 404

    Estazolam 412

    Eszopiclone 418

    Flurazepam 423

    Lorazepam 429

    Lormetazepam 440

    Nitrazepam 446

    Oxazepam 452

    Quazepam 461

    Temazepam 467

    Triazolam 474

    Zaleplon 480

    Zolpidem 485

    Zopiclone 490

    Chapter 4 Safe Deprescribing of Gabapentinoids 495

    When and Why to Stop Gabapentinoids 495

    Discussing deprescribing gabapentinoids 504

    Overview of Gabapentinoid Withdrawal Effects 507

    Physical dependence vs addiction in use of gabapentinoids 510

    How to Deprescribe Gabapentinoids Safely 512

    Principles for tapering gabapentinoids 512

    Making up smaller doses of gabapentinoids practically 516

    Other considerations in tapering gabapentinoids 520

    Psychological aspects of tapering gabapentinoids 523

    Tapering gabapentinoids in practice 525

    Management of complications of gabapentinoid discontinuation 532

    Tapering Guidance for Specific Gabapentinoids 537

    Gabapentin 538

    Pregabalin 546

    Index 553